AR062508A1 - Derivados de 4-(n-azacicloaquil) anilidas como moduladores de los canales de potasio - Google Patents

Derivados de 4-(n-azacicloaquil) anilidas como moduladores de los canales de potasio

Info

Publication number
AR062508A1
AR062508A1 ARP070103756A ARP070103756A AR062508A1 AR 062508 A1 AR062508 A1 AR 062508A1 AR P070103756 A ARP070103756 A AR P070103756A AR P070103756 A ARP070103756 A AR P070103756A AR 062508 A1 AR062508 A1 AR 062508A1
Authority
AR
Argentina
Prior art keywords
alkyl
chr6
cycloalkyl
independently selected
3alkyl
Prior art date
Application number
ARP070103756A
Other languages
English (en)
Inventor
Jean Michel Vernier
Jim Zhen Wu
Gary Lee Larson
Ian Wayne Cheney
La Rosa Martha Alicia De
Huanming Chen
Original Assignee
Huanming Chen
Vernier Jean Michael
Jim Zhen Wu
Gary Lee Larson
Rosa Martha A De
Ian Wayne Cheney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huanming Chen, Vernier Jean Michael, Jim Zhen Wu, Gary Lee Larson, Rosa Martha A De, Ian Wayne Cheney filed Critical Huanming Chen
Publication of AR062508A1 publication Critical patent/AR062508A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dichos compuestos pueden abrir, o modular de otra manera, los canales de potasio dependientes del voltaje. Potencialmente son de utilidad en el tratamiento y la prevencion de enfermedades y trastornos afectados por la activacion o modulacion de los canales ionicos de potasio. Un ejemplo de dichas afecciones es el accidente cerebrovascular. Reivindicacion 1: Un compuesto de la formula (1) caracterizado porque R1 y R2, son, independientemente, H, CN, halogeno, NH2, CH2CN, OH, NO2, CH2F, CHF2, CF3, CF2CF3, alquilo C1-6, C(=O)alquilo C1-6, NH-alquilo C1-6, N(alquilo C1-6)-alquilo C1-6, NHC(=O)alquilo C1-6, C(=O)N(CH3)2, C(=O)N(Et)2, C(=O)NH2, C(=O)NH-alquilo C1-6, SO2NH2, NHSO2-alquilo C1-6, C(=O)Oalquilo C1-6, OC(=O)alquilo C1-6, Oalquilo C1-6, Salquilo C1-6, cicloalquilo C3-6, (CH2)mcicloalquilo C3-6, cicloalquenilo C3-6, (CH2)mcicloalquenilo C3-6, alquenilo C2-6, alquinilo C2-6, Ar, (CH2)mtienilo, (CH2)mimidazolilo, (CH2)mpirazilo, (CH2)moxazolilo, (CH2)misoxazolilo, (CH2)mtiazolilo, (CH2)misotiazolilo, (CH2)mfenilo, (CH2)mpirrolilo, (CH2)mpiridilo, o (CH2)mpirimidinilo, donde m = 0, 1 o 2, Ar es un grupo aromático mono o bicíclico de 5 a 10 miembros, que opcionalmente contiene 1-4 heteroátomos en el anillo seleccionados independientemente de N, O y S; o R1 y R2, junto con los átomos de carbono en el anillo a los cuales se enlazan, forman un anillo fusionado de 5 o 6 miembros, cuyo anillo puede ser saturado, insaturado o aromático, el cual opcionalmente contiene uno o dos heteroátomos seleccionados independientemente de O, N, y S; R' es H, halogeno, fenilo, 2-(N, N-dimetilamino)etilo, CF3, Oalquilo C1-3 o alquilo C1-3; R3 y R4 son, independientemente, H, CN, halogeno, CF3, OCF3, Oalquilo C1-3, o alquilo C1-3; X es O o S; Y es O oS; q = 1 o 0; R5 es alquilo C1-6, (CHR6)wcicloalquilo C3-6, (CHR6)wCH2cicloalquilo C3-6, CH2(CHR6)wcicloalquilo C3-6, CR6=CH-cicloalquilo C3-6, CH=CR6-cicloalquilo C3-6, (CHR6)wcicloalquenilo C5-6, CH2(CHR6)cicloalquenilo C5-6, alquenilo C2-6, alquinilo C2-6, Ar, (CHR6)wAr, CH2(CHR6)wAr, o (CHR6)wCH2Ar, donde w = 0, 1, 2 o 3, Ar es un grupo aromático mono o bicíclico de 5 a 10 miembros, que opcionalmente contiene 1-4 heteroátomos en el anillo seleccionados independientemente de N, O, y S; R6 es H o alquilo C1-3 donde todos los grupos cicloalquilo y cicloalquenilo opcionalmente contienen uno o dos heteroátomos en el anillo seleccionados independientemente de N, O, y S; donde todos los grupos alquilo, cicloalquilo, alquenilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, alquinilo, arilo, y heteroarilo en R1, R2, R', R3, R4, R5, R6, y Ar son opcionalmente sustituidos con uno o dos sustituyentes seleccionados independientemente de alquilo C1-3, halogeno, OH, OEt, OMe, CN, CH2F, OCF3, y CF3 y donde, adicionalmente, todos los grupos cicloalquilo y heterocicloalquilo son opcionalmente sustituidos con un grupo carbonilo.
ARP070103756A 2006-08-23 2007-08-23 Derivados de 4-(n-azacicloaquil) anilidas como moduladores de los canales de potasio AR062508A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83994106P 2006-08-23 2006-08-23

Publications (1)

Publication Number Publication Date
AR062508A1 true AR062508A1 (es) 2008-11-12

Family

ID=39107384

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103756A AR062508A1 (es) 2006-08-23 2007-08-23 Derivados de 4-(n-azacicloaquil) anilidas como moduladores de los canales de potasio

Country Status (23)

Country Link
US (1) US8293911B2 (es)
EP (1) EP2061465B1 (es)
JP (1) JP5419691B2 (es)
KR (1) KR20090079191A (es)
CN (1) CN101563085A (es)
AR (1) AR062508A1 (es)
AU (1) AU2007288253B2 (es)
BR (1) BRPI0716715B1 (es)
CA (1) CA2661462C (es)
CL (1) CL2007002455A1 (es)
DK (1) DK2061465T3 (es)
ES (1) ES2420960T3 (es)
IL (1) IL197161A (es)
MX (1) MX2009002002A (es)
NO (1) NO343575B1 (es)
NZ (1) NZ575652A (es)
PL (1) PL2061465T3 (es)
PT (1) PT2061465E (es)
RU (1) RU2009110172A (es)
SG (1) SG174095A1 (es)
TW (1) TW200827339A (es)
WO (1) WO2008024398A2 (es)
ZA (1) ZA200901977B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
DK2061465T3 (da) 2006-08-23 2013-07-08 Valeant Pharmaceuticals Int Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (zh) 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CA2728915A1 (en) 2008-06-24 2010-01-21 Valeant Pharmaceuticals International Benzyloxy anilide derivatives useful as potassium channel modulators
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
AU2010247849B2 (en) 2009-05-12 2015-11-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
ES2528404T3 (es) 2009-05-12 2015-02-10 Bristol-Myers Squibb Company Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2012004698A1 (en) * 2010-07-08 2012-01-12 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
IN2014CN02806A (es) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
CN103073455B (zh) 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
CN108250128A (zh) * 2012-09-27 2018-07-06 江苏先声药业有限公司 作为钾通道调节剂的化合物
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
EP3468947A4 (en) * 2016-06-10 2020-01-08 SciFluor Life Sciences, Inc. FLUORINATED 2-AMINO-4- (SUBSTITUTED AMINO) PHENYLCARBAMATE DERIVATIVES
US10329516B2 (en) * 2016-12-20 2019-06-25 International Flavors & Fragrances Inc. Organoleptic compounds
CA3085450A1 (en) * 2017-12-13 2019-06-20 Scifluor Life Sciences, Inc. Fluorinated 4-(substituted amino)phenyl carbamate derivatives
US11466012B2 (en) 2018-01-10 2022-10-11 Allinky Biopharma Tetrahydroisoquinoline compounds
ES2964409T3 (es) 2018-05-11 2024-04-05 Xenon Pharmaceuticals Inc Procedimientos para potenciar la biodisponibilidad y la exposición de un abridor de canal de potasio dependiente de voltaje
CN110511220B (zh) * 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
AU2019366312A1 (en) 2018-10-22 2021-05-20 Novartis Ag Crystalline forms of potassium channel modulators
EP3917907A1 (en) 2019-01-29 2021-12-08 Universitá Degli Studi Di Salerno Modulators of potassium ion channels and uses thereof
TW202128627A (zh) * 2019-10-10 2021-08-01 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
BR112022008580A2 (pt) * 2019-11-08 2022-08-09 Xenon Pharmaceuticals Inc Métodos para tratar transtornos depressivos
EP4069211A1 (en) 2019-12-06 2022-10-12 Xenon Pharmaceuticals Inc. Use of a kv7 potassium channel opener for treating pain
CN114057641A (zh) * 2020-08-07 2022-02-18 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用
AU2022220675A1 (en) * 2021-02-09 2023-09-21 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia
MX2023009313A (es) 2021-02-09 2023-08-16 Xenon Pharmaceuticals Inc Terapia conjunta para el tratamiento de trastornos convulsivos.
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用
EP4074696A4 (en) 2021-10-27 2024-01-31 Shanghai Zhimeng Biopharma, Inc. POTASSIUM CHANNEL REGULATOR COMPOUND, PRODUCTION AND USE THEREOF
WO2023125935A1 (zh) * 2021-12-31 2023-07-06 上海翰森生物医药科技有限公司 苯并哌啶衍生物调节剂、其制备方法和应用
CN116478068A (zh) 2022-01-14 2023-07-25 中国科学院上海药物研究所 一种高选择性kcnq4钾通道激动剂、其制备方法和用途
US20240101531A1 (en) 2022-06-08 2024-03-28 Xenon Pharmaceuticals Inc. Pyridinamine derivatives and their use as potassium channel modulators
WO2024050389A1 (en) * 2022-08-30 2024-03-07 Biohaven Therapeutics Ltd. Combination therapies including metal channel activators and nmda receptor antagonists
WO2024067819A1 (zh) * 2022-09-30 2024-04-04 上海翰森生物医药科技有限公司 含哌啶多环类衍生物调节剂、其制备方法和应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181803A (en) 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
EP0110091B1 (de) 1982-10-27 1987-01-21 Degussa Aktiengesellschaft 2-Amino-3-Acylamino-6-benzylamino-pyridin-Derivate mit anti-epileptischer Wirkung
EP0189788B1 (de) 1985-01-23 1989-09-13 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
DE3663775D1 (en) 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
JP2583067B2 (ja) 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (es) 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
USRE38115E1 (en) 1994-09-22 2003-05-06 Center For Neurologic Study Dextromethorphan and an oxidase inhibitor for treating intractable conditions
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
ES2421306T3 (es) 1994-12-12 2013-08-30 Omeros Corporation Solución de irrigación y procedimiento para inhibir el dolor, la inflamación y los espasmos
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
WO1999007411A1 (fr) 1997-08-08 1999-02-18 Chugai Seiyaku Kabushiki Kaisha Remedes contre les complications du diabete
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
JP2000143510A (ja) 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
BR9916162A (pt) 1998-12-14 2001-09-04 Cellegy Pharma Inc Composição e método para o tratamento de um distúrbio anorretal e para controlar a dor associada com o mesmo
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
BR0008847A (pt) 1999-03-10 2001-12-26 Warner Lambert Co Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas
US6436923B1 (en) 1999-03-17 2002-08-20 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
KR20020024300A (ko) 1999-07-06 2002-03-29 피터 지. 스트링거 편두통을 치료하기 위한 선택적 ｉＧｌｕＲ5 수용체 길항제
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
WO2001010380A2 (en) 1999-08-04 2001-02-15 Icagen, Inc. Benzanilides as potassium channel openers
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
NZ527771A (en) 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AU2002338333A1 (en) 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
US6831080B2 (en) * 2001-05-31 2004-12-14 Bristol-Myers Squibb Company Cinnamide derivatives as KCNQ potassium channel modulators
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
AU2003202115A1 (en) 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
AUPS110302A0 (en) * 2002-03-14 2002-04-18 Biomolecular Research Institute Limited Novel chalcone derivatives and uses thereof
CA2486092A1 (en) 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2003106454A1 (en) * 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd 1h-isoquinoline-oxazolidinone derivaties and their use as antibacterial agents
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
WO2004047743A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
ATE488231T1 (de) 2002-12-23 2010-12-15 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
EP1578740B1 (en) 2002-12-27 2007-03-21 H. Lundbeck A/S 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system
CA2519061A1 (en) 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
AU2004222626B2 (en) 2003-03-21 2010-06-24 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
US20060264496A1 (en) 2003-04-25 2006-11-23 H. Lundbeck A/S Substituted indoline and indole derivatives
MXPA05012463A (es) 2003-05-27 2006-01-30 Altana Pharma Ag Combinaciones farmaceuticas de un inhibidor de bomba protonica y un compuesto que modifica la motilidad gastrointestinal.
US20050070570A1 (en) * 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
EP1667978B1 (en) * 2003-09-23 2013-09-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
JP2007532676A (ja) 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリジン
JP2007536229A (ja) 2004-05-03 2007-12-13 デューク・ユニバーシティー 体重減少に作用するための組成物
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
JPWO2006054513A1 (ja) 2004-11-19 2008-05-29 キッセイ薬品工業株式会社 神経因性疼痛の予防又は治療剤
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
AU2006220130B2 (en) 2005-03-03 2011-07-28 H. Lundbeck A/S Substituted pyridine derivatives
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
DK2061465T3 (da) 2006-08-23 2013-07-08 Valeant Pharmaceuticals Int Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
CN101578259A (zh) 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物

Also Published As

Publication number Publication date
JP5419691B2 (ja) 2014-02-19
WO2008024398B1 (en) 2008-08-14
AU2007288253A1 (en) 2008-02-28
CA2661462A1 (en) 2008-02-28
BRPI0716715A2 (pt) 2013-09-03
AU2007288253B2 (en) 2013-05-02
TW200827339A (en) 2008-07-01
ES2420960T3 (es) 2013-08-28
JP2010501568A (ja) 2010-01-21
IL197161A (en) 2015-07-30
BRPI0716715B1 (pt) 2021-07-06
NO343575B1 (no) 2019-04-08
SG174095A1 (en) 2011-09-29
DK2061465T3 (da) 2013-07-08
EP2061465A2 (en) 2009-05-27
PT2061465E (pt) 2013-07-15
ZA200901977B (en) 2010-02-24
KR20090079191A (ko) 2009-07-21
PL2061465T3 (pl) 2014-03-31
CA2661462C (en) 2015-09-29
IL197161A0 (en) 2009-12-24
CN101563085A (zh) 2009-10-21
WO2008024398A3 (en) 2008-06-26
US20080139610A1 (en) 2008-06-12
RU2009110172A (ru) 2010-09-27
MX2009002002A (es) 2009-07-22
WO2008024398A2 (en) 2008-02-28
EP2061465B1 (en) 2013-04-10
CL2007002455A1 (es) 2008-04-18
US8293911B2 (en) 2012-10-23
NO20091183L (no) 2009-05-08
EP2061465A4 (en) 2011-03-16
NZ575652A (en) 2011-08-26

Similar Documents

Publication Publication Date Title
AR062508A1 (es) Derivados de 4-(n-azacicloaquil) anilidas como moduladores de los canales de potasio
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR082985A1 (es) INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
EA201100037A1 (ru) Органические соединения
CO6700838A2 (es) Compuestos sustituidos de banzamida
EA201001371A1 (ru) Конденсированные пиримидиноновые соединения как модуляторы trpv3
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
AR079486A1 (es) Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas.
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
EA201390633A1 (ru) Новые вещества для повторно перерабатываемых эпоксидных смол
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR073406A1 (es) Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.
AR054484A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
AR043837A1 (es) Pirazoles sustituidos
CO6170406A2 (es) Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
EA201891378A1 (ru) Полициклические соединения в качестве ингибиторов тирозинкиназы брутона
ECSP109958A (es) Derivados de pirimidina 934
CO6260005A2 (es) Composiciones agricolas que comprenden dialquil amidas como solvente
BR112014010644A2 (pt) novos derivados de aril-quinolina
RU2013141849A (ru) Композиции и способы применения сложноэфирных производных биматопроста
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica
CO6270319A2 (es) Benzotiazoles como moduladores del receptor de ghrelina

Legal Events

Date Code Title Description
FB Suspension of granting procedure